In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Conjugate Efpeglenatide | Synthetic analog Liraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Conjugate | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 91 | 4,766 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 17 (17 in people) | 805 (793 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 2 | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Efpeglenatide | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weight | 2525 | 1,1171067491 |
| Body weight |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
1111 |
83481717 |
| Adverse eventsWhole body | 66 | 50449311 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 1010 | 185185 |
|---|
| Cardiovascular eventsCardiovascular | 1919 | 13313111 |
|---|
| LipidsMetabolic and weight | 22 | 14313733 |
|---|
| Kidney functionKidney and urinary | 66 | 1049932 |
|---|
| PharmacokineticsPharmacology | 99 | 969231 |
|---|
| Gastrointestinal motilityGastrointestinal | 22 | 26251 |
|---|
| Immune responseImmune and inflammation | 11 | 981 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Liraglutide differs from Glucagon-like peptide 1 (7-37) at 1 position and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
2 trials · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Hanmi Pharmaceutical Company Limited209 participantsFeb 2014 to Apr 2015
Type 2 Diabetes
Hanmi Pharmaceutical Company Limited44 participantsDec 2013 to est. Dec 2014
Diabetes Mellitus
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Efpeglenatide | Liraglutide |
|---|---|---|
| Glycemic controlEndocrine and hormonesCompared as: difference from placebo, in % | 0.3 to 0.38% HbA1c reduction Dose studied: 4 mg or 6 mg once weekly, 6 mg or 8 mg once every 2 weeks20 weeksn not reported2022 | −1.09% HbA1c difference Dose studied: 1.8 mg once daily26 weeksn = 3442009 |
| Body weightMetabolic and weightCompared as: difference from placebo, in kg | 5.6 to 7.3 kg Weight reduction Dose studied: 4 mg or 6 mg once weekly, 6 mg or 8 mg once every 2 weeks20 weeksn not reported2022 | 5.3 kg |
| Adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 5 to 19% Discontinuation due to adverse events Dose studied: 4 mg once weekly, 6 mg once weekly, 6 mg once every 2 wk, or 8 mg once every 2 wk20 weeksn not reported2019 |
0.3 to 0.38%
HbA1c reduction
Dose studied: 4 mg or 6 mg once weekly, 6 mg or 8 mg once every 2 weeks20 weeksn not reported2022
−1.09%
HbA1c difference
Dose studied: 1.8 mg once daily26 weeksn = 3442009
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Efpeglenatide | Liraglutide |
|---|---|---|
| LipidsCardiovascularCompared as: difference from placebo, in lipids | No comparable result 2 randomized-trial results measure it in another way or another unit. | 21 lipids Lipids decreased 26 weeksn = 1022021 |
Body weight difference
16 weeksn = 972017
7.9% Discontinuation due to adverse events Dose studied: up to 1.8 mg/dup to 104 weeksn = 1,9912022 |
5.6 to 7.3 kg
Weight reduction
Dose studied: 4 mg or 6 mg once weekly, 6 mg or 8 mg once every 2 weeks20 weeksn not reported2022
5.3 kg
Body weight difference
16 weeksn = 972017
5 to 19%
Discontinuation due to adverse events
Dose studied: 4 mg once weekly, 6 mg once weekly, 6 mg once every 2 wk, or 8 mg once every 2 wk20 weeksn not reported2019
7.9%
Discontinuation due to adverse events
Dose studied: up to 1.8 mg/dup to 104 weeksn = 1,9912022
| Gastrointestinal motilityGastrointestinalCompared as: difference from placebo, in % | No comparable result 2 randomized-trial results measure it in another way or another unit. | −31.7% Reduction in large bowel transit time · Shown as a change. The study reports a reduction in large bowel transit time of this size. Dose studied: 1.8 mg/day26 weeksn = 482020 |
|---|
| Kidney functionKidney and urinaryCompared as: difference from placebo, in % | No comparable result 5 randomized-trial results measure it in another way or another unit. | −32% UAER reduction · Shown as a change. The study reports a uaer reduction of this size. Dose studied: 1.8 mg/d12 weeksn = 272017 |
|---|
| PharmacokineticsPharmacologyCompared as: difference from placebo, in minutes | No comparable result 7 randomized-trial results measure it in another way or another unit. | 15 minutes tmax delay Dose studied: 1.8 mgn = 182011 |
|---|
| Cardiovascular eventsCardiovascularCompared as: value in the arm that got the peptide, in events/1000 person-years | No comparable result 10 randomized-trial results measure it in another way or another unit. | 1.54 events/1000 person-years Event rate · liraglutide 3.0 mg Dose studied: 3.0 mgn = 5,9082018 |
|---|
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | No comparable result 10 randomized-trial results measure it in another way or another unit. | 21% Nausea · liraglutide 1.8 mg Dose studied: 1.8 mg once daily26 weeksn = 9112013 |
|---|
| Immune responseImmune and inflammationCompared as: share of people in the arm that got the peptide, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | 9.8% participants with anti-liraglutide antibodies Dose studied: 1.8 mg once daily26 weeksn not reported2009 |
|---|
No comparable result
2 randomized-trial results measure it in another way or another unit.
21 lipids
Lipids decreased
26 weeksn = 1022021
No comparable result
2 randomized-trial results measure it in another way or another unit.
−31.7%
Reduction in large bowel transit time · Shown as a change. The study reports a reduction in large bowel transit time of this size.
Dose studied: 1.8 mg/day26 weeksn = 482020
No comparable result
5 randomized-trial results measure it in another way or another unit.
−32%
UAER reduction · Shown as a change. The study reports a uaer reduction of this size.
Dose studied: 1.8 mg/d12 weeksn = 272017
No comparable result
7 randomized-trial results measure it in another way or another unit.
15 minutes
tmax delay
Dose studied: 1.8 mgn = 182011
No comparable result
10 randomized-trial results measure it in another way or another unit.
1.54 events/1000 person-years
Event rate · liraglutide 3.0 mg
Dose studied: 3.0 mgn = 5,9082018
No comparable result
10 randomized-trial results measure it in another way or another unit.
21%
Nausea · liraglutide 1.8 mg
Dose studied: 1.8 mg once daily26 weeksn = 9112013
No comparable result
1 randomized-trial result measure it in another way or another unit.
9.8%
participants with anti-liraglutide antibodies
Dose studied: 1.8 mg once daily26 weeksn not reported2009